Skip to main content
Transparency data

Executive summary

Updated 27 October 2026

The ACNFP CCP Subgroup came together in a ‘problem solving’ session to support ACNFP reviews of Cell-Cultivated Product (CCP) dossiers. This session was an opportunity to discuss wider topics looking at current and future issues.

Subgroup members reviewed the draft Suitability Checklist used by the FSA during novel food assessments. The discussion focused on whether the checklist is proportionate, scientifically robust, and practical to apply across a diverse range of CCP applications, in which the importance of scientific judgement, proportionality, and flexibility being emphasised. It was agreed that the checklist should support assessors in determining whether an application contains sufficient information to proceed to assessment, rather than operate as a strict tick-box exercise and provided a series of specific recommendations to improve the usability of the checklist within the FSA. Overall, the subgroup concluded that the checklist is a valuable tool for dossier review and recommended revisions to reinforce a risk-based, proportionate approach.

Next the subgroup reviewed the FAO Food Safety Aspects of Cell-based Food document and broadly agreed that it was a comprehensive and well-structured document. Subgroup members felt that most relevant hazards associated with CCP production were covered, making it a valuable resource for applicants. Subgroup members highlighted the absence of consideration for integrated viral sequences and genetic stability considerations, including epigenetic changes. These discussions also explored the regulatory treatment of genetically altered CCPs and public perceptions and public confidence in CCPs.

The identity of CCPs was discussed and there was broad agreement that this should be assessed on a case-by-case basis, focusing on the characteristics of the product being authorised and consumed. The subgroup concluded that there is unlikely to be a single definition of CCP identity applicable to all products. Instead, a flexible, science-based approach will be required to ensure that each product is appropriately characterised and assessed according to its individual features and risk profile e.g. whether there is inclusion of scaffold or growth media.

The subgroup discussed the future of CCPs including CCPs as mixtures, edible scaffolds and assessment of dietary exposure. Participants broadly supported using established novel food approaches, including conservative exposure scenarios and consideration of intended uses. Discussion highlighted the importance of focusing assessment efforts on identified hazards and taking a proportionate, risk-based approach where products are considered like existing food ingredients. The discussion emphasised the need for flexibility as technologies evolve, whilst ensuring sufficient information is available to support robust safety assessments and future regulatory decision-making.

Finally, the subgroup discussed potential future developments in CCPs and considered how emerging technologies may influence future safety assessments. Members highlighted the rapid pace of innovation in areas such as genetic engineering, novel cell types, advanced scaffolds and large-scale production systems, recognising that future products may differ significantly from those currently under review. The discussion emphasised the importance of maintaining a flexible, technology-neutral regulatory approach that focuses on the characteristics and safety of a product rather than the specific technology used to create it. Participants also noted the need for ongoing monitoring of scientific developments, periodic review of guidance, and continued engagement with industry to ensure regulatory approaches remain fit for purpose as the sector evolves. Overall, there was broad confidence that current risk assessment principles provide a strong foundation, whilst recognising the need to remain adaptable as new technologies emerge

The discussions from this session will be used by the FSA to improve the current risk assessment methods, monitor future developments in CCPs and update its approach.